TherapeuticsMD (TXMD) Net Income towards Common Stockholders: 2010-2025
Historic Net Income towards Common Stockholders for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $102,000.
- TherapeuticsMD's Net Income towards Common Stockholders rose 342.86% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $229,000, marking a year-over-year decrease of 64.82%. This contributed to the annual value of $131,000 for FY2024, which is 105.08% up from last year.
- According to the latest figures from Q3 2025, TherapeuticsMD's Net Income towards Common Stockholders is $102,000, which was up 1,600.00% from $6,000 recorded in Q2 2025.
- In the past 5 years, TherapeuticsMD's Net Income towards Common Stockholders registered a high of $127.2 million during Q2 2022, and its lowest value of -$47.4 million during Q3 2021.
- In the last 3 years, TherapeuticsMD's Net Income towards Common Stockholders had a median value of -$17,000 in 2025 and averaged -$433,727.
- In the last 5 years, TherapeuticsMD's Net Income towards Common Stockholders spiked by 398.12% in 2022 and then crashed by 122.67% in 2025.
- TherapeuticsMD's Net Income towards Common Stockholders (Quarterly) stood at $50.1 million in 2021, then slumped by 41.68% to $29.2 million in 2022, then tumbled by 97.75% to $658,000 in 2023, then crashed by 79.03% to $138,000 in 2024, then skyrocketed by 342.86% to $102,000 in 2025.
- Its Net Income towards Common Stockholders was $102,000 in Q3 2025, compared to $6,000 in Q2 2025 and -$17,000 in Q1 2025.